Contributed Abstracts
Hall 1 (Salt Palace Convention Center)
A Novel Hematopoietic Progenitor Cell (HPC) Mobilization Regimen, Utilizing Bortezomib and Filgrastim (G-CSF), for Patients Undergoing Autologous HPC Transplant (AHPCT) for Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL)
Sunil Abhyankar, University of Kansas Medical Center;
Shaun DeJarnette, The University of Kansas Hospital;
Jennifer Bunch, University of Kansas Medical Center;
Dean Merkel, University of Kansas Hospital;
Siddhartha Ganguly, University of Kansas Medical Center;
Omar Aljitawi, University of Kansas Medical Center;
Elizabeth Harvey, University of Kansas Medical Center;
Kelly Daniels, University of KS Hospital;
Joseph McGuirk, University of Kansas Medical Center
BEAM or ICE?
Fevzi Altuntas, Ankara Oncology Hospital;
Sinem civriz Bozdag, Ankara Oncology Hospital;
Itir Demiriz, Ankara Oncology Hospital;
Aysegul Tetik, Ankara Oncology Hospital;
Omur Kayikci, Ankara Oncology Hospital;
Murat Cinarsoy, Ankara Oncology Hospital;
Sinem Namdaroglu, Ankara Oncology Hospital;
Bilge Ugur, Ankara Oncology Hospital;
Emre Tekgunduz, Ankara Oncology Hospital
Successful Autologous Cord Blood Transplantation in a Child with Acquired Severe Aplastic Anemia
David Buchbinder, MD, Children's Hospital of Orange County;
Steven M Neudorf, MD, Children's Hospital of Orange County;
Richard Childs, MD, National Institutes of Health;
Carla Daum, RN, CPON, Children's Hospital of Orange County;
Loan Hsieh, MD, Children's Hospital of Orange County;
Van Huynh, MD, Children's Hospital of Orange County;
Ivan Kirov, MD, Children's Hospital of Orange County;
Edna Klinger, RN, BS, Children's Hospital of Orange County;
Nancy Kuntz, RN, PNP, Children's Hospital of Orange County;
David Margolis, MD, Medicial College of Wisconsin;
Theodore B Moore, MD, David Geffen School of Medicine at UCLA;
Geetha Puthenveetil, MD, Children's Hospital of Orange County;
Elyssa Rubin, MD, Children's Hospital of Orange County;
Leonard Sender, MD, UC Irvine Medical Center;
Amit Soni, MD, Children's Hospital of Orange County;
Jill Stites, FNP, Children's Hospital of Orange County;
Lilibeth Torno, MD, Children's Hospital of Orange County;
Diane Jean Nugent, MD, Children's Hospital of Orange County
Redefining Engraftment Syndrome: The New Mayo Clinic Criteria
Brian Leslie Burnette, MD, Mayo Clinic Foundation;
Morie Gertz, MD, Mayo Clinic;
Shaji Kumar, MD, Mayo Clinic;
Martha Lacy, MD, Mayo Clinic;
Francis Buadi, MD, Mayo Clinic;
Suzanne Hayman, MD, Mayo Clinic;
David Dingli, Mayo Clinic;
David J Inwards, MD, Mayo Clinic;
Patrick B Johnston, Mayo Clinic;
Ivana N Micallef, MD, Mayo Clinic;
Luis F Porrata, MD, Mayo Clinic;
William Hogan, MBBCh, Mayo Clinic;
Mark R Litzow, MD, Mayo Clinic;
Mrinal Patnaik, MD, Mayo Clinic;
Shahrukh Hashmi, MD, MPH, Mayo Clinic;
Nelson Leung, MD, Mayo Clinic Foundation;
Bekele Afessa, MD, Mayo Clinic Foundation;
Dennis Gastineau, MD, Mayo Clinic;
Stephen M Ansell, MD, PhD, Mayo Clinic;
Shernan Holtan, MD, Mayo Clinic;
Angela Dispenzieri, MD, Mayo Clinic Rochester, The William J. Von Liebig Transplant Center
Deferred Dosing of Granulocyte Colony Stimulating Factors in Autologous Hematopoietic Transplantation for Multiple Myeloma
Stacy Campos, Center For Cell and Gene Therapy;
James Cox, Pharm.D., The Methodist Hospital;
Romelia May, CCRC, CCRA, CCRP, Baylor College of Medicine;
MF Wu, Baylor College of Medicine;
Hao Liu, PhD, Baylor College of Medicine;
Carlos A. Ramos, MD, Baylor College of Medicine;
Helen E. Heslop, MD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital;
Malcolm K. Brenner, MD, PhD, Baylor College of Medicine, Texas Children's Hospital;
George Carrum, MD, Baylor College of Medicine;
Rammurti Kamble, MD, Baylor College of Medicine Center for Cell and Gene Therapy
Evaluation of Antioxidant Enzyme Levels of Glutathione Peroxidase in Patients Undergoing A Autologous Hematopoietic STEM CELL
Thayna NOGUEIRA Santos Jr., STUDENT, Federal University of Ceara;
Fernando Duarte, md, Federal University of Ceara;
Maritza cavalcante Barbosa, student, Federal university of Ceara;
Talyta Ellen de Jesus dos Santos, student, Federal University of Ceara;
Romelia Pinheiro Gonçalves, Professor, Federal University of Ceara
A Multicenter Analysis of Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor for PB Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies
Farrukh Tauseef Awan, MD, Georgia Health Sciences University;
Samith Kochuparambil, MD, Georgia Health Sciences University;
Michael Craig, MD, West Virginia University;
Aaron Cumpston, PharmD, West Virginia University Hospitals;
Sonia Leadmon, BSBA, West Virginia University Hospitals;
David DeRemer, PharmD, BCOP, Medical College of Georgia;
Kathy Watkins, West Viriginia University;
Jeremy Pantin, MD, Georgia Health Sciences University;
Vamsi Kota, Georgia Health Sciences University;
Anand Jillella, MD, Georgia Health Science University;
Mehdi Hamadani, MD, West Virginia University - Mary Babb Randolph Cancer Center
Hematopoietic Cell Yield Declines Predictably Over Time During Apheresis
Allison F Hazlett, MS, VCU Massey Cancer Center;
Elaine Wang, VCU Massey Cancer Center;
Jennifer Anderson, VCU Massey Cancer Center;
Harold Chung, MD, VCU Massey Cancer Center;
John Michael McCarty, MD, VCU Massey Cancer Center;
William Clark, MD, MS, VCU Massey Cancer Center;
Catherine H. Roberts, PhD, VCU Massey Cancer Center;
Amir Ahmed Toor, MD, VCU Massey Cancer Center
Fluid Retention and Weight Gain During Peripheral Blood Hematopoietic Stem Cell Mobilization in Light Chain Amyloidosis
Josh Howell, UT MD Anderson Cancer Center;
Simrit Parmar, MD, UT MD Anderson Cancer Center;
Qaiser Bashir, MD, UT MD Anderson Cancer Center;
Nina Shah, MD, UT MD Anderson Cancer Center;
Chitra Hosing, MD, UT MD Anderson Cancer Center;
Uday Popat, MD, UT MD Anderson Cancer Center;
Megan Cornelison, PA, MD Anderson;
Richard E. Champlin, MD, MD Anderson Cancer Center;
Muzaffar Qazilbash, MD, UT MD Anderson Cancer Center
Influence of Diabetes On Autologous Hematopoietic Stem Cell Mobilization
Michael Long, Texas Transplant Institute;
Anthony Sanchez, Texas Transplant Institute;
Jill Folkert, APN, Methodist Hospital;
Gayla Nagy, RN, Methodist Hospital;
Wilma Cain, Texas Transplant Institute;
Carlos Bachier, MD, Texas Transplant Institute;
Paul J. Shaughnessy, MD, Texas Transplant Institute
Hematopoietic CELL Transplantation (HCT)-Specific Comorbidity INDEX in Autologous STEM CELL Transplant Indicates People with Advanced Age and Increased Comorbidity INDEX Should BE Hosptialized Through Engraftment
Jill MacPherson, DNP, RN, FNP-BC, AOCNP, Texas Transplant Institute;
Ashley Simpson, PA-C, Texas Transplant Institute;
Mary Krivoy, RN, BSN, OCN, Methodist Hospital;
Kathleen Canty, MSN, Methodist Hospital;
Hannah Sowell, RN, Methodist Hospital;
Carlos Bachier, MD, Texas Transplant Institute;
Paul J. Shaughnessy, MD, Texas Transplant Institute
Autologous Hematopoietic Stem Cell Transplant (aHSCT) Is a Safe and Reasonable Treatment in Patients with Primary Systemic Amyloidosis (AL amyloidosis)
Akshata Pandit, B.S, The Ohio State University College of Medicine;
Lai Wei, Ph.D, The Ohio State University;
Patrick Elder, MS, Arthur G. James Cancer Institute;
William Falk, B.S, The Ohio State University;
Megan Sell, MS, CNP, The Ohio State University;
Craig C Hofmeister, MD, Ohio State University Medical Center;
Don M Benson, MD, PhD, The Ohio State University;
Sam Penza, MD, The Ohio State University;
Leslie A Andritsos, MD, The Ohio State University;
Rebecca Klisovic, MD, The Ohio State University;
Sumithira Vasu, MBBS, Ohio State University Medical Center;
William Blum, MD, The Ohio State University;
Steven M Devine, MD, The Ohio State University;
Samantha Jaglowski, MD, Ohio State University Medical Center;
Yvonne Efebera, MD, The Ohio State University
Safety and Efficacy From Intravenous Busulfan with PK-Directed Dosed Adjustment and Bortezomib Conditioning Regimen in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation
Voravit Ratanatharathorn, MD, Karmanos Cancer Institute;
Edward A. Stadtmauer, MD, University of Pennsylvania;
Rosa F. Yeh, PharmD, Seattle Cancer Care Alliance;
Cesar O Freytes, MD, South Texas Veterans Health Care System, University of Texas Health Science Center at San Antonio;
Juan J. Toro, MD, MSci, South Texas Veterans Health Care System, University of Texas Health Science Center at San Antonio;
Gorgun Akpek, MD, M.H.S., F.A.C.P., University of Maryland Medical Center;
Entezam Sahovic, MD, Western Pennsylvania Cancer Institute;
Guido J. Tricot, MD, PhD, University of Utah School of Medicine;
Paul J. Shaughnessy, MD, Texas Transplant Institute;
Darrell J. White, MD, MSc, FRCPC, FACP, Queen Elizabeth II Health Sciences Centre and Dalhousie University;
Tulio E. Rodriguez, MD, Loyola University Chicago Medical Center;
Scott R. Solomon, MD, The Blood and Marrow Transplant Program at Northside Hospital;
Louie H. Yu, BS, Seattle Cancer Care Alliance;
Shiva Patil, PhD, Otsuka Pharmaceutical Development & Commercialization, Inc.;
Yiping Sun, PhD, Otsuka Pharmaceutical Development & Commercialization, Inc.;
Elizabeth Armstrong, MS, Otsuka Pharmaceutical Development & Commercialization, Inc.;
Angela Smith, MS, PA, Otsuka Pharmaceutical Development & Commercialization, Inc.;
Agnes Elekes, MD, Otsuka Pharmaceutical Development & Commercialization, Inc.;
Kazunobu Kato, MD, PhD, Otsuka Pharmaceutical Development & Commercialization, Inc.;
Donna E. Reece, MD, Ontario Cancer Institute
Method of Autologous Stem Cell Mobilization Does Not Influence Transplant Outcome
Anthony Sanchez, Texas Transplant Institute;
Michael Long, Texas Transplant Institute;
Jill Folkert, APN, Methodist Hospital;
Gayla Nagy, RN, Methodist Hospital;
Carlos Bachier, MD, Texas Transplant Institute;
Paul J. Shaughnessy, MD, Texas Transplant Institute
HDM/ SCT for AL Amyloidosis - a Single Institution 12 Year Experience
Emma C. Scott, MD, Oregon Health and Science University;
Tibor Kovacsovics, MD, Oregon Health and Science University;
Stephen Smith, MD, Oregon Health and Science University;
Farnoush Abar, MD, Oregon Health and Science University;
Alex Stentz, BA, Oregon Health and Science University;
Rachel Frires, BA, Oregon Health and Science University;
James Dibb, Oregon Health and Science University;
William Dibb, BA, Oregon Health and Science University;
Stephen Heitner, MD, Oregon Health & Science University;
Richard T. Maziarz, MD, Oregon Health and Science University
Salvage Autologous Stem Cell Transplantation for Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Single Institution Experience
Saad J Sirop, MD, Mayo Clinic;
Thomas M Habermann, MD, Mayo Clinic;
William R Macon, MD, Mayo Clinic;
Kay M Ritsow, Mayo Clinic;
Stephen M Ansell, MD, PhD, Mayo Clinic;
Joseph P Colgan, MD, Mayo Clinic;
Patrick B Johnston, Mayo Clinic;
Svetomir N Markovic, MD, PhD, Mayo Clinic;
Ivana N Micallef, MD, Mayo Clinic;
Carrie A Thompson, MD, Mayo Clinic;
Luis F Porrata, MD, Mayo Clinic;
James A Martenson, MD, Mayo Clinic;
Thomas E Witzig, MD, Mayo Clinic;
Grzegorz S Nowakowski, MD, Mayo Clinic;
David J Inwards, MD, Mayo Clinic
Intravenous Compared to Oral Busulfan with Cyclophosphamide for Autologous Hematopoietic Progenitor Cell Transplant Conditioning for Plasma Cell Myeloma
Ronald Sobecks, MD, Cleveland Clinic Taussig Cancer Institute;
Lisa Rybicki, MS, Cleveland Clinic Taussig Cancer Institute;
Robert M Dean, MD, Cleveland Clinic Taussig Cancer Institute;
Donna Abounader, Cleveland Clinic Taussig Cancer Institute;
S. Andresen, Cleveland Clinic Taussig Cancer Institute;
Hien Duong, MD, Cleveland Clinic Taussig Cancer Institute;
Fred Reu, MD, Cleveland Clinic Taussig Cancer Institute;
Brian Bolwell, MD, Cleveland Clinic Taussig Cancer Institute;
Ed Copelan, MD, Cleveland Clinic Taussig Cancer Institute;
Matt E. Kalaycio, MD, Cleveland Clinic Taussig Cancer Institute
Impact of Antiviral Prophylaxis Duration On Varicella Zoster Virus Infection Rates in Recipients of Autologous Hematopoietic Cell Transplantation
Quoc Truong, MD, West Virginia University;
Lauren Veltri, M.D, West Virginia University;
Abraham Kanate, MD, West Virginia University;
Mehdi Hamadani, MD, West Virginia University - Mary Babb Randolph Cancer Center;
Michael Craig, MD, West Virginia University;
Aaron Cumpston, PharmD, West Virginia University Hospitals
Results of a Phase 2 Clinical Trial Testing the Efficacy of Plerixafor in Combination with Chemotherapy in the Mobilization of Autologous Blood Hematopoietic Progenitor Cells
Edmund K. Waller, MD, PhD, Emory University;
Heather Renfroe Johnson, Emory University Winship Cancer Institute;
Neera Jagirdar, Emory University Winship Cancer Institute;
Cynthia Gaylor, RN, Emory University Hospital;
Carol Lipscomb, RN, Emory University Winship Cancer Institute;
Christopher Flowers, MD, MS, Emory University Winship Cancer Institute;
Jonathan Kaufman, MD, Emory University Winship Cancer Institute;
H. Jean Khoury, MD, Emory University Winship Cancer Institute;
Amelia Langston, MD, Emory University Winship Cancer Institute;
MaryJo Lechowicz, MD, Emory University Winship Cancer Institute;
Sagar Lonial, MD, Emory University Winship Cancer Institute;
Ajay Nooka, MD MPH, Emory University Winship Cancer Institute;
Rajni Sinha, MD, MRCP, Emory University Winship Cancer Institute;
R. Donald Harvey, PharmD, Emory University Winship Cancer Institute
Impact of Bone Marrow Neuropathy On the Outcome of Autologous Stem Cell Transplantation (ASCT) for Lymphoma
Basem M. William, MD, MRCP, University Hospitals Case Medical Center;
Nermin Kady, Michigan State University;
Anamarija M. Perry, MD, University of Manitoba;
Kimberly Klinetobe, University of Nebraska Medical Center;
Robert Gregory Bociek, MD, University of Nebraska Medical Center;
Philip J. Bierman, MD, University of Nebraska Medical Center;
Julie M Vose, MD, University of Nebraska Medical Center;
James O Armitage, MD, University of Nebraska Medical Center;
Dennis Weisenburger, MD, City of Hope National Medical Center;
Julia V. Busik, PhD, Michigan State University
Fractionated Stem Cell Infusions for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant
Kevin Wood, MD, Weill Cornell Medical Center;
Sergio A. Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Guenther Koehne, MD, PhD, Memorial Sloan-Kettering Cancer Center;
David Chung, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Hani Hassoun, MD, Memorial Sloan-Kettering Cancer Center;
Nikoletta Lendvai, Memorial Sloan-Kettering Cancer Center;
Alexander Lesokhin, Memorial Sloan-Kettering Cancer Center;
Elizabeth Hoover, Memorial Sloan-Kettering Cancer Center;
Sean Devlin, PhD, Memorial Sloan-Kettering Cancer Center;
Heather Landau, MD, TBD
Plerixafor Overcomes the Adverse Effect of Diabetes On Hematopoietic Progenitor Cell Mobilization
Chunzhi Xia, MD, Medical college of Wisconsin;
Xiaobo Zhong, MS, Medical college of Wisconsin;
Dhakal Binod, MD, Medical college of Wisconsin;
Jonathan Thompson, MD, Medical College of Wisconsin, Hematology/Oncology;
Timothy Fenske, MD, Medical College of Wisconsin;
Carolyn Taylor, PhD, Medical College of Wisconsin;
Jean Esselmann, Medical College of Wisconsin;
Anand Padmanabhan, MD, PhD, Blood center of Wisconsin;
Parameswaran N. Hari, MD, MRCP, MS, CIBMTR / Medical College of Wisconsin
Reducing Inappropriate Testing Following NCCN and IDSA Guidelines in Autologous Stem Cell Transplant (SCT) Patients
Deborah Yolin Raley, PA-C, MS, Dana-Farber Cancer Institute;
Brett Glotzbecker, MD, Dana-Farber Cancer Institute;
Joseph Antin, MD, Dana-Farber Cancer Institute;
Robert J. Soiffer, MD, Dana-Farber Cancer Institute;
Edwin P. Alyea III, MD, Dana-Farber Cancer Institute
![[Visit Client Website]](images/banner.gif)